It’s not too often that a biotech company marches into the FDA and asks permission to run human tests of a remedy derived from parasitic worms. But the agency will likely be entertaining just such a request sometime in the next couple of months, when Coronado Biosciences files an Investigational New Drug (IND) application for CNDO-201, a brew that contains 2,500 eggs from a parasite found in pigs. The company—which is moving from New York to Boston in August—plans to test the therapy in patients suffering from Crohn’s disease, an autoimmune condition that strikes the intestinal tract.
